Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allos Looks To Boost Lymphoma Drug Folotyn's Prospects With Mundipharma Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Currently the only approved drug for relapsed or refractory PTCL in the U.S., Folotyn may soon have competition from Celgene's Istodax.

You may also be interested in...



Investors Balk At AMAG-Allos Proposed Marriage

An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.

Investors Balk At AMAG-Allos Proposed Marriage

An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.

Celgene Pays $340 Million For Gloucester And Its New Drug

Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.

Related Content

Topics

UsernamePublicRestriction

Register

PS072220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel